Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Br J Pharmacol. 2010 Dec;161(8):1751-62. doi: 10.1111/j.1476-5381.2010.00990.x.
Haem oxygenase 1 (HO-1) is an inducible protein that plays a major protective role in conditions such as ischaemia-reperfusion injury and inflammation. In this study, we have investigated the role of haem arginate (HA) in human male subjects in the modulation of HO-1 expression and its correlation with the GT length polymorphism (GT(n)) in the promoter of the HO-1 gene.
In a dose-escalation, randomized, placebo-controlled trial, seven healthy male subjects with a homozygous short (S/S) and eight with a long (L/L) GT(n) genotype received intravenous HA. HO-1 protein expression and mRNA levels in peripheral blood monocytes, bilirubin, haptoglobin, haemopexin and haem levels were analysed over a 48 h observation period.
We found that the baseline mRNA levels of HO-1 were higher in L/L subjects, while protein levels were higher in S/S subjects. HA induced a dose-dependent increase in the baseline corrected area under the curve values of HO-1 mRNA and protein over 48 h. The response of HO-1 mRNA was more pronounced in L/L subjects but the protein level was similar across the groups.
HA is an effective inducer of HO-1 in humans irrespective of the GT(n) genotype. The potential therapeutic application of HA needs to be evaluated in clinical trials.
血红素加氧酶 1(HO-1)是一种诱导蛋白,在缺血再灌注损伤和炎症等情况下发挥主要保护作用。在这项研究中,我们研究了精氨酸血红素(HA)在人类男性受试者中对 HO-1 表达的调节作用及其与 HO-1 基因启动子中 GT 长度多态性(GT(n))的相关性。
在一项剂量递增、随机、安慰剂对照试验中,7 名具有纯合短(S/S)GT(n)基因型和 8 名具有长(L/L)GT(n)基因型的健康男性受试者接受了静脉内 HA 治疗。在 48 小时的观察期间,分析外周血单核细胞、胆红素、触珠蛋白、血红素结合蛋白和血红素水平的 HO-1 蛋白表达和 mRNA 水平。
我们发现,L/L 受试者的 HO-1 mRNA 基线水平较高,而 S/S 受试者的蛋白水平较高。HA 诱导 HO-1 mRNA 和蛋白的基线校正曲线下面积在 48 小时内呈剂量依赖性增加。L/L 受试者的 HO-1 mRNA 反应更为明显,但蛋白水平在各组之间相似。
HA 是人类 HO-1 的有效诱导剂,与 GT(n)基因型无关。HA 的潜在治疗应用需要在临床试验中进行评估。